Geode Capital Management LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

Geode Capital Management LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,667,920 shares of the company's stock after acquiring an additional 1,561,036 shares during the period. Johnson & Johnson accounts for 0.6% of Geode Capital Management LLC's holdings, making the stock its 20th biggest position. Geode Capital Management LLC owned 2.40% of Johnson & Johnson worth $8,321,881,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Oregon Pacific Wealth Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth approximately $949,000. Horan Securities Inc. lifted its stake in shares of Johnson & Johnson by 1.3% during the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after buying an additional 90 shares during the period. Strategic Financial Concepts LLC grew its holdings in shares of Johnson & Johnson by 57.9% during the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock valued at $501,000 after buying an additional 1,271 shares during the last quarter. Lord Abbett & CO. LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at $69,859,000. Finally, Quantinno Capital Management LP increased its holdings in shares of Johnson & Johnson by 29.0% in the third quarter. Quantinno Capital Management LP now owns 219,599 shares of the company's stock valued at $35,588,000 after purchasing an additional 49,307 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Johnson & Johnson Price Performance

JNJ stock traded down $4.36 during trading on Friday, hitting $155.46. The stock had a trading volume of 6,020,692 shares, compared to its average volume of 7,751,833. The company's 50-day moving average price is $159.63 and its two-hundred day moving average price is $156.01. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock has a market capitalization of $374.63 billion, a P/E ratio of 23.34, a PEG ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the business posted $2.29 earnings per share. Johnson & Johnson's quarterly revenue was up 5.3% on a year-over-year basis. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on JNJ shares. Wells Fargo & Company dropped their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Bank of America increased their price objective on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a "neutral" rating in a research note on Wednesday, March 5th. Royal Bank of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Finally, Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $171.33.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.